Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

179
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
179
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

142
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
142
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

325
Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
325
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

242
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
242
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

228
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
228
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

331
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
331

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Synthesis, Spectroscopy Characterization and Biological Evaluation of La(III), Eu(III) and Gd(III) Complexes with Ampicillin: In Vitro Antimicrobial, Cytotoxic and Antiproliferative Activities and Theoretical Frameworks.

Molecules (Basel, Switzerland)·2026
Same author

RISK FACTORS FOR RENAL CALCULI IN PATIENTS WITH CROHN'S DISEASE.

Arquivos de gastroenterologia·2025
Same author

Cytotoxicity of norstictic acid derivatives, a depsidone from <i>Ramalina anceps</i> Nyl.

Turkish journal of chemistry·2024
Same author

Semi-automated data collection from electronic health records in a stroke unit in Brazil.

Arquivos de neuro-psiquiatria·2021
Same author

Antibacterial potencial of 12 Lichen species.

Anais da Academia Brasileira de Ciencias·2021
Same author

The Impact of Electronic Media on Patients with Inflammatory Bowel Disease.

Risk management and healthcare policy·2021

Related Experiment Video

Updated: Jun 30, 2025

A Retrospective Study on Endoscopic Surgery for the Treatment of Paravertebral Abscess in Spinal Tuberculosis Patients
03:47

A Retrospective Study on Endoscopic Surgery for the Treatment of Paravertebral Abscess in Spinal Tuberculosis Patients

Published on: October 25, 2024

222

RATE OF INFECTION (TUBERCULOSIS) IN BRAZILIANS IBD PRIVATE PATIENTS: FOLLOW-UP 15 YEARS.

Didia B Cury1, Liana C B Cury2, Ana C Micheletti3

  • 1Centro de Doenças Inflamatórias Intestinais, Clínica Scope, Campo Grande, MS, Brasil.

Arquivos De Gastroenterologia
|March 21, 2024
PubMed
Summary

Biological therapy for inflammatory bowel diseases (IBD) increases the risk of latent tuberculosis (LTB). Continuous patient monitoring is crucial, as longer anti-TNF exposure significantly elevates LTB risk.

More Related Videos

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates
10:04

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates

Published on: September 5, 2017

18.8K
A Functional Whole Blood Assay to Measure Viability of Mycobacteria, using Reporter-Gene Tagged BCG or M.Tb BCG lux/M.Tb lux
08:10

A Functional Whole Blood Assay to Measure Viability of Mycobacteria, using Reporter-Gene Tagged BCG or M.Tb BCG lux/M.Tb lux

Published on: September 14, 2011

13.9K

Related Experiment Videos

Last Updated: Jun 30, 2025

A Retrospective Study on Endoscopic Surgery for the Treatment of Paravertebral Abscess in Spinal Tuberculosis Patients
03:47

A Retrospective Study on Endoscopic Surgery for the Treatment of Paravertebral Abscess in Spinal Tuberculosis Patients

Published on: October 25, 2024

222
Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates
10:04

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates

Published on: September 5, 2017

18.8K
A Functional Whole Blood Assay to Measure Viability of Mycobacteria, using Reporter-Gene Tagged BCG or M.Tb BCG lux/M.Tb lux
08:10

A Functional Whole Blood Assay to Measure Viability of Mycobacteria, using Reporter-Gene Tagged BCG or M.Tb BCG lux/M.Tb lux

Published on: September 14, 2011

13.9K

Area of Science:

  • Gastroenterology and Immunology
  • Infectious Disease Epidemiology

Background:

  • Latent tuberculosis (LTB) is a concern in patients treated with immunosuppressants, particularly anti-tumor necrosis factor (anti-TNF) agents.
  • Inflammatory bowel diseases (IBD) patients on these therapies face an increased risk of opportunistic infections, including tuberculosis (TB).
  • A 15-year follow-up in Brazil assessed TB infection rates in private IBD patients.

Purpose of the Study:

  • To evaluate the risk of biological therapy inducing latent tuberculosis (LTB) in inflammatory bowel diseases (IBD) patients.
  • To identify risk factors associated with LTB development during a 15-year period in Brazil.
  • To assess the impact of anti-TNF therapy duration on LTB risk.

Main Methods:

  • Retrospective analysis of an IBD patient database from a private clinic in Brazil.
  • Tuberculin skin testing (TST) and chest X-rays were performed annually before and during treatment.
  • Patients were stratified using the Montreal classification, considering risk factors for TB development.

Main Results:

  • Age and gender were identified as significant risk factors for LTB.
  • Crohn's disease (CD) and ulcerative colitis (UC) patients on adalimumab and infliximab showed higher LTB incidence.
  • Increased duration of anti-TNF exposure was significantly associated with a higher risk of LTB.

Conclusions:

  • Biological therapies, especially anti-TNFs, pose a real risk of inducing latent tuberculosis in IBD patients.
  • Continuous and permanent monitoring of IBD patients undergoing biological therapy is essential.
  • Longer exposure to anti-TNF agents correlates with a greater risk of developing LTB.